SEC Form 4 · accession 0001140361-17-045528
Spyre Therapeutics, Inc. · SYRE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Anthony G. Quinn
Officer — Interim CEO · Director
Period of report
Dec 6, 2017
Accepted (ET)
Dec 8, 2017 · 7:06 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001636282
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Dec 6, 2017 | P | 4,888 | $4.9248 | A | 32,009 | D | |
| Common StockF2 | Dec 7, 2017 | P | 2,800 | $4.9882 | A | 34,809 | D | |
| Common StockF3 | Dec 8, 2017 | P | 600 | $5.065 | A | 35,409 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.77 to $5.05 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F2Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $4.88 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.
- F3Represents a weighted average purchase price per share. These shares were purchased in multiple transactions at prices ranging from $5.01 to $5.10 per share. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares purchased at each separate price within the range.